Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Litton

Showing results (61-70 of 166) with videos related to

Pageof 17
Sort By:
Annals of Surgical Oncology|September 28, 2011
Triple-negative breast cancer is not a contraindication for breast conservationFarrell C Adkins, Ana Maria Gonzalez-Angulo, Xiudong Lei, et al.
Breast Cancer Research and Treatment|June 20, 2018
Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypesTakahiro Kogawa, Takeo Fujii, Tamer M Fouad, et al.
Plastic and Reconstructive Surgery|May 3, 2011
Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapyRanjna Sharma, Loren L Rourke, Steven J Kronowitz, et al.
Cancer|September 14, 2011
Earlier age of onset of BRCA mutation-related cancers in subsequent generationsJennifer K Litton, Kaylene Ready, Huiqin Chen, et al.
Cancer|July 16, 2011
Early onset HER2-positive breast cancer is associated with germline TP53 mutationsAmal Melhem-Bertrandt, Jasmina Bojadzieva, Kaylene J Ready, et al.
Clinical Breast Cancer|July 19, 2011
Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtypeRachel L Theriault, Jennifer K Litton, Elizabeth A Mittendorf, et al.
Breast Cancer Research : BCR|May 25, 2012
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapyAbigail S Caudle, Tse-Kuan Yu, Susan L Tucker, et al.
Clinical Immunology (Orlando, Fla.)|March 1, 2019
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumorsG Travis Clifton, Kaitlin M Peace, Jarrod P Holmes, et al.
Clinical Breast Cancer|December 3, 2014
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomesNapa Parinyanitikul, Xiudong Lei, Mariana Chavez-MacGregor, et al.
Cancer|March 13, 2009
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutationJennifer K Litton, Shannon N Westin, Kaylene Ready, et al.
Pageof 17

Showing results (61-70 of 166) with videos related to

Sort By:
Pageof 17
Annals of Surgical Oncology|September 28, 2011
Triple-negative breast cancer is not a contraindication for breast conservationFarrell C Adkins, Ana Maria Gonzalez-Angulo, Xiudong Lei, et al.
Breast Cancer Research and Treatment|June 20, 2018
Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypesTakahiro Kogawa, Takeo Fujii, Tamer M Fouad, et al.
Plastic and Reconstructive Surgery|May 3, 2011
Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapyRanjna Sharma, Loren L Rourke, Steven J Kronowitz, et al.
Cancer|September 14, 2011
Earlier age of onset of BRCA mutation-related cancers in subsequent generationsJennifer K Litton, Kaylene Ready, Huiqin Chen, et al.
Cancer|July 16, 2011
Early onset HER2-positive breast cancer is associated with germline TP53 mutationsAmal Melhem-Bertrandt, Jasmina Bojadzieva, Kaylene J Ready, et al.
Clinical Breast Cancer|July 19, 2011
Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtypeRachel L Theriault, Jennifer K Litton, Elizabeth A Mittendorf, et al.
Breast Cancer Research : BCR|May 25, 2012
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapyAbigail S Caudle, Tse-Kuan Yu, Susan L Tucker, et al.
Clinical Immunology (Orlando, Fla.)|March 1, 2019
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumorsG Travis Clifton, Kaitlin M Peace, Jarrod P Holmes, et al.
Clinical Breast Cancer|December 3, 2014
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomesNapa Parinyanitikul, Xiudong Lei, Mariana Chavez-MacGregor, et al.
Cancer|March 13, 2009
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutationJennifer K Litton, Shannon N Westin, Kaylene Ready, et al.
Pageof 17